2026-04-20T09:20:10-05:00 2025-12-31 050409384 KAHN LITWIN RENZA & CO LTD 951 NORTH MAIN STREET PROVIDENCE RI 02904 990 2025-01-01 810756743 TARGET ALS FOUNDATION INC TARG 6465922541 244 MADISON AVE 1025 NEW YORK NY 10016 KENNETH DEVANEY TREASURER 6465922541 2026-04-17 1 PATRICK J MARTIN P00283486 4012742001 2026-04-17 2025 2025-03-06 01:10:19Z KENNETH DEVANEY 244 MADISON AVE 1025 NEW YORK NY 10016 48375695 0 X TARGETALS.ORG X 2015 NY OUR MISSION IS TO BREAK DOWN BARRIERS TO ALS RESEARCH TO FIND EFFECTIVE TREATMENTS. BY UNITING ACADEMIA, THE PHARMA AND BIOTECH INDUSTRY, GOVERNMENT, VENTURE CAPITAL, RELATED NONPROFITS, AND THE ALS COMMUNITY, WE AIM TO OVERCOME THE CHALLENGES THAT HAVE LONG HINDERED PROGRESS, BRINGING HOPE AND TANGIBLE ADVANCEMENTS TO THOSE AFFECTED BY THIS DEVASTATING DISEASE. 14 14 18 36 0 0 0 29724385 0 0 0 3535375 0 2225 0 33261985 0 18765868 0 0 0 3855667 0 0 1758767 0 2997179 0 25618714 0 7643271 128911762 136912637 4351675 1853620 124560087 135059017 X OUR MISSION IS TO BREAK DOWN BARRIERS TO ALS RESEARCH TO FIND EFFECTIVE TREATMENTS. BY UNITING ACADEMIA, THE PHARMA AND BIOTECH INDUSTRY, GOVERNMENT, VENTURE CAPITAL, RELATED NONPROFITS, AND THE ALS COMMUNITY, WE AIM TO OVERCOME THE CHALLENGES THAT HAVE LONG HINDERED PROGRESS, BRINGING HOPE AND TANGIBLE ADVANCEMENTS TO THOSE AFFECTED BY THIS DEVASTATING DISEASE. 0 0 21006355 18765868 RESEARCH WE FUND:TARGET ALS IS THE LARGEST AND MOST IMPACTFUL PRIVATE FUNDER OF ALS RESEARCH WORLDWIDE. THANKS TO THE GENEROUS TRUST PLACED IN US BY OUR DONORS, WE CAN DIRECT RESOURCES TO THE MOST PROMISING IDEAS AND EMERGING SCIENTIFIC LEADERS ACROSS THE GLOBE. OUR FUNDED PROJECTS HAVE A HIGH SUCCESS RATE, DELIVERING MEANINGFUL RESULTS TO ADVANCE IDEAS FROM EARLY TO LATE STAGE RESEARCH. IN 2025, WE CONTINUED TO EXPAND FUNDING OPPORTUNITIES, DRIVING NEARLY $12M INTO INNOVATION ACROSS 151 GRANTS IN THREE CRITICAL AREAS:UNDERSTANDING ALS BIOLOGY: ADVANCING INSIGHTS INTO THE ROOT CAUSES OF DISEASE TO IDENTIFY NEW DRUG TARGETS.ACCELERATING DRUG DISCOVERY: SUPPORTING PROOF-OF-CONCEPT STUDIES THAT PAVE THE WAY TOWARD CLINICAL TRIALS.DEVELOPING BIOMARKERS: ENABLING EARLIER DIAGNOSIS, IDENTIFYING ALS SUBTYPES, AND MONITORING DISEASE PROGRESSION WITH PRECISIONEVERY GRANT THAT TARGET ALS FUNDS IS TIED TO A DELIBERATE STRATEGY AND A LONG-RANGE VISION FOR THE FIELD, ENSURING THAT PROMISING IDEAS MOVE THROUGH THE FULL RESEARCH PATHWAY: UNCOVERING DISEASE BIOLOGY, IDENTIFYING AND REFINING NEW THERAPEUTIC TARGETS OR BIOMARKERS, VALIDATING THEM IN RIGOROUS MODELS, GENERATING TRANSLATIONAL DATA, AND PREPARING THE STRONGEST CANDIDATES FOR CLINICAL DEVELOPMENT. OUR FUNDING ALLOCATION REFLECTS WHERE THE STRONGEST IDEAS EMERGE. THE DISTRIBUTION OF OUR FUNDING ISN'T SET BY QUOTAS OR PERCENTAGES. IT'S SHAPED BY WHERE THE MOST COMPELLING SCIENCE IS HAPPENING. EACH YEAR, WE INVEST IN THE PROPOSALS WITH THE CLEAREST BIOLOGICAL RATIONALE, THE STRONGEST EVIDENCE, AND THE GREATEST POTENTIAL TO ADVANCE THE FIELD. RESEARCH WE ENABLE:TARGET ALS CONTINUES TO BREAK DOWN BARRIERS TO PROGRESS BY OFFERING NO-STRINGS-ATTACHED ACCESS TO CRITICAL TOOLS AND RESOURCES THROUGH OUR RESEARCH CORES. THESE SHARED RESOURCES ADDRESS LONGSTANDING CHALLENGES IN ALS RESEARCH THAT HAVE HISTORICALLY SLOWED DISCOVERY: LIMITED ACCESS, HIGH COSTS, AND LACK OF STANDARDIZATION. THE RESEARCH CORES ACCELERATE DRUG DISCOVERY AND BIOMARKER DEVELOPMENT WHILE FOSTERING COLLABORATION ACROSS THE GLOBAL ALS COMMUNITY. IN 2025, TARGET ALS INVESTED OVER $8M TO EMPOWER SCIENTISTS WITH THE MATERIALS, DATA, AND INFRASTRUCTURE THEY NEED TO DRIVE PROGRESS FROM THE BENCH TO THE CLINIC. FROM OUR POSTMORTEM TISSUE CORE TO THE LONGITUDINAL BIOFLUIDS CORE POWERED BY OUR GLOBAL NATURAL HISTORY STUDY (GNHS) AND OPEN-ACCESS DATA ENGINE, TARGET ALS PROVIDES RESEARCHERS WORLDWIDE WITH STATE-OF-THE-ART BIOSAMPLES, DATASETS, ANTIBODIES, AND MORE, WITH NO REACHTHROUGH ON INTELLECTUAL PROPERTY (IP). THESE TOOLS ARE AVAILABLE TO BOTH ACADEMIA AND INDUSTRY, ENSURING THAT SCIENTIFIC BREAKTHROUGHS CAN MOVE SWIFTLY AND COLLABORATIVELY TOWARD THERAPIES FOR PEOPLE LIVING WITH ALS. TO DATE, MORE THAN 1,750 PROJECTS HAVE RELIED ON THESE RESOURCES, SPANNING BASIC BIOLOGY, TARGET VALIDATION, BIOMARKER DISCOVERY, AND THERAPEUTIC DEVELOPMENT. AND THE MOMENTUM IS ONLY GROWING: OVER 500 RESEARCHERS HAVE ACCESSED OUR DATA ENGINE, WHILE GLOBAL CONSORTIA OF PREEMINENT SCIENTISTS ARE WORKING TOGETHER WITH TARGET ALS FUNDS TO SHARE DATA, REPLICATE FINDINGS, AND AMPLIFY IMPACT.RESEARCH WE CONDUCT:ALS IS A DISEASE THAT AFFECTS PEOPLE OF EVERY RACE AND ETHNICITY AROUND THE WORLD. HOWEVER, CLINICAL TRIALS ENROLL PRIMARILY PEOPLE OF WHITE, EUROPEAN DESCENT RESULTING IN A BIASED, INCOMPLETE VIEW OF DISEASE BIOLOGY ACROSS THE ALS GLOBAL POPULATION. THE ALS GLOBAL RESEARCH INITIATIVE (AGRI) IS THE ONLY COMPREHENSIVE, GLOBAL RESEARCH EFFORT THAT BRINGS TOGETHER TWO COMPLEMENTARY CLINICAL STUDIES DESIGNED TO UNCOVER THE CAUSES OF ALS AND IDENTIFY NEW BIOMARKERS THAT CAN DIAGNOSE THE DISEASE EARLIER, TRACK ITS PROGRESSION, AND PREDICT OUTCOMES. THESE STUDIES PROVIDE RESEARCHERS UNPRECEDENTED ACCESS TO PATIENT DATA AND BIOSAMPLES WORLDWIDE, RAPIDLY ACCELERATING NEW DISCOVERIES AND DRIVING PROGRESS TOWARD MORE EFFECTIVE THERAPIES. ULTIMATELY, INCLUSIVE RESEARCH STRENGTHENS SCIENTIFIC VALIDITY, IMPROVES PATIENT OUTCOMES, AND HELPS ENSURE THAT BREAKTHROUGHS BENEFIT EVERYONE, NOT JUST A SUBSET OF THE POPULATION. THROUGHOUT THE YEAR, WE INVESTED OVER $1.5M, WHICH FUELED AGRI'S BOLD GOAL: BRING THE WORLD TOGETHER TO TACKLE ALS FROM EVERY ANGLE. THROUGH OUR GLOBAL NATURAL HISTORY STUDY (GNHS) AND COMMUNITYBASED POP-UP CLINICS, WE'RE MAKING ALS RESEARCH MORE INCLUSIVE, MORE IMMEDIATE, AND MORE COLLABORATIVE THAN EVER BEFORE. 21006355 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 18 0 18 1 0 0 0 0 0 0 0 0 0 0 0 0 X 14 14 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY X KENNETH DEVANEY 6465922541 244 MADISON AVE 1025 NEW YORK NY 10016 DANIEL L DOCTOROFF BOARD CHAIR 1.00 X X 0 0 0 JOHN DUNLOP BOARD MEMBER 1.00 X 0 0 0 BRAD S KARP BOARD MEMBER 1.00 X 0 0 0 ZACH W HALL BOARD MEMBER 1.00 X 0 0 0 STORY LANDIS BOARD MEMBER 1.00 X 0 0 0 SARAH SHEIKH BOARD MEMBER 1.00 X 0 0 0 ALISA DOCTOROFF BOARD MEMBER 1.00 X 0 0 0 ALLISON JAFFIN BOARD MEMBER 1.00 X 0 0 0 ANDY BERNDT BOARD MEMBER 1.00 X 0 0 0 CHRIS HERNDERSON BOARD MEMBER 1.00 X 0 0 0 RICHARD HARGREAVES BOARD MEMBER 1.00 X 0 0 0 CAROL HO BOARD MEMBER 1.00 X 0 0 0 STACY WENINGER BOARD MEMBER 1.00 X 0 0 0 ERIC DANE BOARD MEMBER (AS OF 12/25) 1.00 X 0 0 0 MANISH RAISINGHANI PRESIDENT 40.00 X 404414 0 40841 KENNETH DEVANEY CHIEF OPERATING OFFICER 40.00 X 293699 0 35305 JESSICA CHAPMAN CHIEF DEVELOPMENT OFFICER 40.00 X 240468 0 68984 AMY EASTON VICE PRESIDENT, RESEARCH GROUPS 40.00 X 299898 0 68984 YULIYA RZAD CHIEF GRANTS OFFICER 40.00 X 206142 0 43617 CHRISTINE PROUTY ARANYOS DIRECTOR OF PHILANTHROPY 40.00 X 165242 0 62251 LAURA DUGOM ASSOCIATE DIRECTOR CLINICAL RESEARCH 40.00 X 168857 0 29063 STEPHANIE ISHOO DIRECTOR OF MARKETING & COMMUNICATIONS 40.00 X 165555 0 27314 1944275 0 376359 12 0 1 0 0 29724385 6226324 29724385 3253081 3253081 15396004 15113710 282294 282294 282294 OTHER INCOME 900099 2225 2225 2225 33261985 0 0 3537600 13067691 13067691 5698177 5698177 970997 350438 329004 291555 2080679 425646 1249279 405754 104034 21282 62464 20288 499114 77981 326462 94671 200843 48967 104303 47573 32006 32006 91859 91859 176591 176591 258252 194765 63487 802482 802482 99032 6004 76414 16614 143162 143162 94181 20974 58708 14499 1299614 1289195 8575 1844 25618714 21006355 2853592 1758767 2137916 3278742 8351865 4679056 49311907 45694945 250000 76751 75597 68783323 83184297 128911762 136912637 33343 25316 4318332 1828304 4351675 1853620 X 81346621 91694347 43213466 43364670 124560087 135059017 128911762 136912637 7643271 2855659 0 X 0 1 X 0 0 X 6884826 98356585 79162687 47902882 29724385 262031365 6884826 98356585 79162687 47902882 29724385 262031365 33043073 228988292 3174 24092 407954 2201600 955309 3592129 67784 392 2224 70400 265693894 0.86190 0.86670 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 INVESTMENTS 83184297 C 83184297 X 35941053 2855659 2855659 33085394 176591 176591 33261985 25442123 0 25442123 176591 176591 25618714 PART X, LINE 2: THE FOUNDATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE (IRC). MANAGEMENT BELIEVES THAT THE FOUNDATION OPERATES IN A MANNER CONSISTENT WITH ITS TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVELS. THE FOUNDATION ANNUALLY FILES IRS FORM 990, RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX, REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES, GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE FOUNDATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGRESS. 1 CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANTS TO RECIPIENTS, PROGRAM SERVICES DATA ENGINE EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS & PROGRAM SERVICES DATA ENGINE & POSTMORTEM TISSUE CORE 213943 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS IN VIVO TARGET VALIDATION PROJECTS, DATA ENGINE, POSTMORTEM TISSUE CORE, LONGITUDINAL BIOFLUIDS CORE, REAGENTS CORE 4793803 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS TO RECIPIENTS & PROGRAM SERVICES DATA ENGINE, POSTMORTEM TISSUE CORE, REAGENTS CORE 605978 NORTH AMERICA 0 0 PROGRAM SERVICES DATA ENGINE, POSTMORTEM TISSUE CORE, REAGENTS CORE SOUTH ASIA 0 0 GRANTS TO RECIPIENTS & PROGRAM SERVICES DATA ENGINE 84453 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES DATA ENGINE 0 0 0 0 0 0 5698177 0 5698177 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 95494 CASH 0 SOUTH ASIA SCIENTIFIC RESEARCH 42325 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 259400 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 50000 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 120000 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 229925 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 0 222965 IN VIVO TARGET VALIDAITON STUDY FMV MIDDLE EAST AND NORTH AFRICA SCIENTIFIC RESEARCH 129979 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 129124 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 119995 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 150000 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 384322 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 125000 CASH 0 SOUTH ASIA SCIENTIFIC RESEARCH 42128 CASH 0 EAST ASIA AND THE PACIFIC SCIENTIFIC RESEARCH 125000 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 130520 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 0 108456 IN VIVO TARGET VALIDAITON STUDY FMV EAST ASIA AND THE PACIFIC SCIENTIFIC RESEARCH 67357 CASH 0 MIDDLE EAST AND NORTH AFRICA SCIENTIFIC RESEARCH 100000 CASH 0 MIDDLE EAST AND NORTH AFRICA SCIENTIFIC RESEARCH 140000 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 215148 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 95844 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 0 187371 IN VIVO TARGET VALIDAITON STUDY FMV EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 342360 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 149896 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 387423 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 124953 CASH 0 EAST ASIA AND THE PACIFIC SCIENTIFIC RESEARCH 21586 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 129935 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 100000 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 130000 CASH 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 371622 CASH 0 MIDDLE EAST AND NORTH AFRICA SCIENTIFIC RESEARCH 235999 CASH 0 31 2 0 0 0 0 0 0 1 CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD 2416 LOS ANGELES CA 90048 951644600 501(C)3 116550 0 SCIENTIFIC RESEARCH COLUMBIA UNIVERSITY 630 WEST 168TH STREET NEW YORK NY 10032 133948652 501(C)3 575116 0 SCIENTIFIC RESEARCH REGENTS OF THE UNIVERSITY OF CALIFORNIA AT SAN DIEGO 9500 GILMAN DR LA JOLLA CA 92093 956006144 501(C)3 461402 0 SCIENTIFIC RESEARCH BANNER SUN HEALTH RESEARCH INSTITUTE 1111 E MCDOWELL RD PHOENIX AZ 85006 450233470 501(C)3 202642 0 SCIENTIFIC RESEARCH BAYLOR COLLEGE OF MEDICINE 1102 BATES AVENUE HOUSTON TX 77030 741613878 501(C)3 60000 0 SCIENTIFIC RESEARCH BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS HENRY ADMINISTRATION BUILDING URBANA IL 61801 376000511 501(C)3 200000 0 SCIENTIFIC RESEARCH DENALI THERAPEUTICS 161 OYSTER POINT BLVD SAN FRANCISCO CA 94080 463872213 501(C)3 100000 0 SCIENTIFIC RESEARCH DIGNITY HEALTH 350 WEST THOMAS ROAD PHOENIX CA 85013 941196203 501(C)3 800313 0 SCIENTIFIC RESEARCH EMORY UNIVERSITY 1762 CLIFTON ROAD SUITE 1400 ATLANTA GA 30322 580566256 501(C)3 386594 0 SCIENTIFIC RESEARCH GEORGETOWN UNIVERSITY 3700 O ST NW WASHINGTON DC 20057 530196603 501(C)3 103074 0 SCIENTIFIC RESEARCH HARVARD UNIVERSITY 1033 MASSACHUSETTS AVE STE 3 CAMBRIDGE MA 02138 042103580 501(C)3 125000 0 SCIENTIFIC RESEARCH JOHN HOPKINS UNIVERSITY 725 WOLFE STREET BALTIMORE MD 21205 520595110 501(C)3 253263 0 SCIENTIFIC RESEARCH LADDER THERAPEUTICS INC 1030 BRITTAN AVE SAN CARLOS CA 94070 861878229 140000 0 SCIENTIFIC RESEARCH MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD SOUTH JACKSONVILLE FL 32224 593337028 501(C)3 579510 0 SCIENTIFIC RESEARCH NATIONAL INSTITUTE OF HEALTH 35A CONVENT DRIVE BETHESDA MD 20892 521983273 GOVERNMENT 110300 0 SCIENTIFIC RESEARCH NEURAL STEM CELL INSTITUTE ONE DISCOVERY DRIVE RENSSELAER NY 12144 203654626 501(C)3 49273 0 SCIENTIFIC RESEARCH NEURODEX INC 27 STRATHMORE ROAD NATICK MA 01760 043230035 128200 0 SCIENTIFIC RESEARCH NORTHWESTERN UNIVERSITY 1201 DAVIS STREET CHICAGO IL 60208 362167817 501(C)3 438968 0 SCIENTIFIC RESEARCH NOVA SOUTHEASTERN UNIVERSITY 3300 S UNIVERSITY DRIVE FORT LAUDERDALE FL 33328 591083502 501(C)3 103087 0 SCIENTIFIC RESEARCH NUCYRNA THERAPEUTICS INC 1296 WORCESTER RD APT 2303 FRAMINGHAM MA 01702 992059436 200000 0 SCIENTIFIC RESEARCH PRINCETON UNIVERSITY 701 CARNEGIE CENTER SUITE 445 PRINCETON NJ 08540 210634501 501(C)3 60000 0 SCIENTIFIC RESEARCH PURDUE UNIVERSITY 610 PURDUE MALL WEST LAFAYETTE IN 47907 351052049 501(C)3 60000 0 SCIENTIFIC RESEARCH QUR ALIS 35 CAMBRIDGEPARK DRIVE 300 CAMBRIDGE MA 02140 814722156 200000 0 SCIENTIFIC RESEARCH REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE 419 SOUTH CIRCLE VIEW DRIVE IRVINE CA 92617 952226406 501(C)3 200000 0 SCIENTIFIC RESEARCH REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 S STATE STREET SUITE 8000A ANN ARBOR MI 48109 386006309 501(C)3 255000 0 SCIENTIFIC RESEARCH REGENTS UNIVERSITY OF CALIFORNIA CHARLES E YOUNG DRIVE WEST LOS ANGELES CA 90095 956006143 501(C)3 150000 0 SCIENTIFIC RESEARCH ROME THERAPEUTICS 201 BROOKLINE AVENUE SUITE 1001 BOSTON MA 02215 833633163 0 184701 COST ACTUAL COST TO INTRODUCE STUDY REPORT INVOICED BY VENDOR SCIENTIFIC RESEARCH SAINT LOUIS UNIVERSITY 1100 SOUTH GRAND BLVD ST LOUIS MO 63101 430654872 501(C)3 125000 0 SCIENTIFIC RESEARCH STANFORD UNIVERSITY 1291 WELCH ROAD PALO ALTO CA 94305 941156365 501(C)3 185000 0 SCIENTIFIC RESEARCH SYNOLIGO BIOTECHNOLOGIES 101 SOUTHCENTER COURT SUITE 800 MORRISVILLE NC 27560 883196281 100000 0 SCIENTIFIC RESEARCH THE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET SUITE 540 BOSTON MA 02114 042697983 501(C)3 375000 0 SCIENTIFIC RESEARCH THE UNIVERSITY OF ALABAMA AT BIRMINGHAM 1720 2ND AVE S AB1230 BIRMINGHAM AL 35294 636005396 501(C)3 298217 0 SCIENTIFIC RESEARCH THOMAS JEFFERSON UNIVERSITY 233 SOUTH 10TH STREET PHILADELPHIA PA 19107 231352651 501(C)3 89962 0 SCIENTIFIC RESEARCH TRACE NEUROSCIENCE 750 GATEWAY BLVD SUITE 200 SAN FRANCISCO CA 94080 990762304 105000 0 SCIENTIFIC RESEARCH TRANSLATIONAL GENOMICS RESEARCH INSTITUTE 445 NORTH 5TH STREET PHOENIX AZ 85004 753065445 501(C)3 125000 0 SCIENTIFIC RESEARCH TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 422 CURIE BOULEVARD PHILADELPHIA PA 19104 231352685 501(C)3 0 210429 COST ACTUAL COST TO INTRODUCE STUDY REPORT INVOICED BY VENDOR SCIENTIFIC RESEARCH TWILIGHT NEURO 100 CUMMINGS CENTER SUITE 207-209 BEVERLY MA 01915 920566170 129400 0 SCIENTIFIC RESEARCH TWIST BIOSCIENCE 681 GATEWAY BLVD SAN FRANCISCO CA 94080 462058888 100000 0 SCIENTIFIC RESEARCH UNIVERSITY OF CALIFORNIA SAN FRANCISCO LOCKBOX 45339 SAN FRANCISCO CA 94145 946036493 501(C)3 731472 0 SCIENTIFIC RESEARCH UNIVERSITY OF CALIFORNIA SANTA BARBARA 6129 BIOLOGY II SANTA BARBARA CA 93106 956006145 501(C)3 290000 0 SCIENTIFIC RESEARCH UNIVERSITY OF MASSACHUSETTS CHAN MEDICAL SCHOOL 366 PLANTATION STREET WORCESTER MA 01605 043167352 501(C)3 100000 0 SCIENTIFIC RESEARCH UNIVERSITY OF PITTSBURGH 3501 FIFTH AVENUE PITTSBURGH PA 15213 250965591 125000 0 SCIENTIFIC RESEARCH UNIVERSITY OF PUERTO RICO PO BOX 365067 SAN JUAN PR 00956 660433762 501(C)3 93789 0 SCIENTIFIC RESEARCH UNIVERSITY OF SOUTHERN CALIFORNIA 3720 S FLOWER ST FL3 LOS ANGELES CA 90089 951642394 501(C)3 260000 0 SCIENTIFIC RESEARCH UNIVERSITY OF VERMONTH AND STATE AGRICULTURAL COLLEGE BEAUMONT AVENUE BURLINGTON VT 05405 030179440 501(C)3 101736 0 SCIENTIFIC RESEARCH WASHINGTON UNIVERSITY 660 SOUTH EUCLID AVENUE ST LOUIS MO 63110 430653611 501(C)3 213046 0 SCIENTIFIC RESEARCH YALE UNIVERSITY PO BOX 2038 NEW HAVEN CT 06521 275024008 501(C)3 100000 0 SCIENTIFIC RESEARCH 36 11 PART I, LINE 2: THE ORGANIZATION USES GRANTS MANAGEMENT SOFTWARE, WHERE ALL INFORMATION IS SAVED RELATING TO EACH RECEIVED APPLICATION. THIS INCLUDES THE SCOPE OF WORK / RESEARCH PROPOSAL, BUDGET, SIGNED CONTRACTS AND AWARD LETTERS, ORGANIZATIONAL INFORMATION SUCH AS EIN AND ADDRESS, PAYMENT RECORDS RECONCILED WITH THE ORGANIZATION'S FINANCIAL SYSTEM, AND SCORED REVIEWS BY ITS INDEPENDENT REVIEW COMMITTEE. X X X 0 0 0 0 0 0 0 0 0 MANISH RAISINGHANI PRESIDENT 404414 0 0 0 0 0 20221 0 20620 0 445255 0 0 0 AMY EASTON VICE PRESIDENT, RESEARCH GROUPS 299898 0 0 0 0 0 14995 0 53989 0 368882 0 0 0 KENNETH DEVANEY CHIEF OPERATING OFFICER 293699 0 0 0 0 0 14685 0 20620 0 329004 0 0 0 JESSICA CHAPMAN CHIEF DEVELOPMENT OFFICER 240468 0 0 0 0 0 14995 0 53989 0 309452 0 0 0 YULIYA RZAD CHIEF GRANTS OFFICER 206142 0 0 0 0 0 10307 0 33310 0 249759 0 0 0 CHRISTINE PROUTY ARANYOS DIRECTOR OF PHILANTHROPY 165242 0 0 0 0 0 8262 0 53989 0 227493 0 0 0 LAURA DUGOM ASSOCIATE DIRECTOR CLINICAL RESEARCH 168857 0 0 0 0 0 8443 0 20620 0 197920 0 0 0 STEPHANIE ISHOO DIRECTOR OF MARKETING & COMMUNICATIO 165555 0 0 0 0 0 8278 0 19036 0 192869 0 0 0 X 16 6226324 FMV 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 TWO INDIVIDUALS SERVING AS OFFICERS/DIRECTORS OF THE ORGANIZATION ARE SPOUSES. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY MANAGEMENT. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL BOARD EXECUTIVE COMMITTEE MEMBERS FOR THEIR REVIEW PRIOR TO SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD OF DIRECTORS ARE ASKED ANNUALLY TO REVIEW THE CONFLICT OF INTEREST POLICY, DISCLOSE ANY POTENTIAL CONFLICTS OF INTEREST AND SIGN-OFF THAT THEY UNDERSTAND THEIR OBLIGATIONS AS A MEMBER OF THE BOARD. THE CONFLICT OF INTEREST POLICY STATES THAT PERIODIC REVIEW BE PERFORMED EVALUATING WHETHER PARTNERSHIP, JOINT VENTURES OR THE LIKE CONFORM WITH THE ORGANIZATION'S WRITTEN POLICIES REGARDING UNAUTHORIZED PRIVATE BENEFIT AND EXCESS BENEFIT TRANSACTIONS. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD CONDUCTS A PERFORMANCE REVIEW AND EVALUATION OF THE PRESIDENT & CEO. THE REVIEW ALSO ESTABLISHES THE INDIVIDUAL'S COMPENSATION. THIS PROCESS INVOLVES THE EVALUATION OF THE INDIVIDUAL AND A REVIEW OF COMPENSATION OF COMPARABLE POSITIONS OBTAINED FROM COMPENSATION SURVEYS. THE BOARD'S DELIBERATION AND DECISION IS DISCUSSED IN EXECUTIVE SESSISION. THE PRESIDENT & CEO ESTABLISHES THE COMPENSATION OF THE SENIOR MANAGEMENT TEAM AND REVIEWS THE PERFORMANCE EVALUATIONS AND RECOMMENDED COMPENSATION WITH THE BOARD. THE EVALUATIONS AND COMPENSATION ARE DISCUSSED WITH THE BOARD ALTHOUGH NO VOTE OF APPROVAL OF THE PRESIDENT & CEO'S DECISION IS REQUIRED. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS (ARTICLES OF INCORPORATION AND BY-LAWS) AVAILABLE UPON REQUEST BY ELECTRONIC MAIL. THE TARGET ALS CONFLICT OF INTEREST POLICY IS AVAILABLE ON OUR WEBSITE: HTTPS://TARGETALS.ORG/OUR-TEAM/. SIMILARLY, ANNUAL FINANCIAL STATEMENTS ARE AVAILABLE HERE: HTTPS://TARGETALS.ORG/FINANCIAL-REPORTS/.